◎ Sugi Atlas

Atlas / Drug / Toripalimab

Toripalimab

drug
On this page

Also known as Anti-pd-i mab-shanghai junshiCHS-007Js-001Js001LoqtorziTAB-001TAB001TeriprizumabToripalimab-tpziTreprizumabTripleitriumabTriprizumabTuoyi

Summary

Toripalimab (CHEMBL4297843) is an approved antibody (ATC L01FF13) targeting PDCD1; indicated across 63 conditions including neoplasm and nasopharyngeal carcinoma; with CIViC clinical evidence for 1 variant-indication association (e.g. TMB High in lung non-small cell carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FF13
  • Targets: 1 (PDCD1)
  • Indications: 63 conditions
  • Clinical trials: 395
  • Precision-oncology evidence (CIViC): 1 variant–indication association

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL4297843
NameToripalimab
TypeAntibody
Max phase4
ATCL01FF13

Also known as: Anti-pd-i mab-shanghai junshi, CHS-007, Js-001, JS-001, Js001, JS001, Loqtorzi, TAB-001, TAB001, Teriprizumab, Toripalimab, Toripalimab-tpzi

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PDCD1programmed cell death 1 (CD279)Binding7.680%Q15116

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): PDCD1.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Co-inhibition by PD-11PDCD1
Potential therapeutics for SARS1PDCD1
PD-L1(CD274) glycosylation and translocation to plasma membrane1PDCD1

Dominant GO biological processes

GO termTargets
B cell apoptotic process1
adaptive immune response1
negative regulation of tolerance induction1
negative regulation of T cell mediated immune response to tumor cell1
negative regulation of B cell apoptotic process1
apoptotic process1
humoral immune response1
negative regulation of inflammatory response1
regulation of immune response1
negative regulation of immune response1
negative regulation of T cell receptor signaling pathway1
negative regulation of T cell activation1
positive regulation of T cell apoptotic process1
regulatory T cell apoptotic process1
immune system process1

Indications & clinical

Indications

63 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
nasopharyngeal carcinoma4MONDO:0015459MONDO:0011871
hepatocellular carcinoma3MONDO:0007256EFO:0000182
lymphoma3MONDO:0005062EFO:0000574
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
cholangiocarcinoma3MONDO:0019087EFO:0005221
triple-negative breast carcinoma3MONDO:0005494EFO:0005537
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
small cell lung carcinoma3MONDO:0008433EFO:0000702
melanoma3MONDO:0005105EFO:0000756
metastatic melanoma3MONDO:0005191EFO:0002617
nasopharyngeal neoplasm3MONDO:0005375EFO:0004252
urothelial carcinoma3MONDO:0040679EFO:0008528
neuroendocrine carcinoma3MONDO:0002120MONDO:0002120
intrahepatic cholangiocarcinoma3MONDO:0003210EFO:1001961
carcinoma of esophagus3MONDO:0019086EFO:0002916
cutaneous melanoma3MONDO:0005012EFO:0000389
Hodgkins lymphoma3MONDO:0004952EFO:0000183
adenocarcinoma3MONDO:0004970MONDO:0003219
head and neck cancer2MONDO:0005627EFO:0006859
colorectal carcinoma2MONDO:0024331EFO:1001951
undifferentiated pleomorphic sarcoma2MONDO:0002142EFO:1001972
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
gastric adenocarcinoma2MONDO:0005036EFO:0000503
sarcoma2MONDO:0005089EFO:0000691
biliary tract neoplasm2MONDO:0005304EFO:0003891
gastric neoplasm2MONDO:0021085MONDO:0001056
breast neoplasm2MONDO:0021100MONDO:0007254
nasal cavity and paranasal sinus lethal midline granuloma2MONDO:0006828MONDO:0019472
squamous cell carcinoma2MONDO:0005096EFO:0000707
malignant pleural mesothelioma2MONDO:0005112EFO:0000770
cervical adenocarcinoma2MONDO:0005153EFO:0001416
soft tissue sarcoma2MONDO:0018078EFO:1001968
hypopharynx cancer2MONDO:0005806MONDO:0021358
salivary gland cancer2MONDO:0004669EFO:0003826
oral cavity squamous cell carcinoma2MONDO:0004958EFO:0000199
lung neoplasm2MONDO:0021117MONDO:0008903
renal cell carcinoma2MONDO:0005086EFO:0000681
malignant pancreatic neoplasm2MONDO:0009831EFO:1000359
rectal cancer2MONDO:0006519EFO:1000657
carcinoma2MONDO:0004993EFO:0000313
ovarian carcinoma2MONDO:0005140EFO:0001075
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
hypopharyngeal carcinoma2MONDO:0005216EFO:0002938
colorectal neoplasm2MONDO:0005335MONDO:0005575
colonic neoplasm1MONDO:0005401EFO:0004288
thrombotic disease1MONDO:0000831MONDO:0000831
liposarcoma1MONDO:0005060EFO:0000569
oral cavity neoplasm1MONDO:0021245EFO:0003868
Epstein-Barr virus infection0MONDO:0005111EFO:0000769

13 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 395.

Phase distribution

PhaseTrials
PHASE2233
PHASE1/PHASE259
PHASE141
PHASE332
Not specified20
PHASE2/PHASE36
PHASE42
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06457503PHASE4RECRUITINGA Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
NCT05291910PHASE4UNKNOWNInetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
NCT04365036PHASE3RECRUITINGA Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
NCT04376866PHASE3RECRUITINGToripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
NCT04772287PHASE3NOT_YET_RECRUITINGAdjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
NCT04778956PHASE3RECRUITINGToripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
NCT05180734PHASE3ACTIVE_NOT_RECRUITINGPD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05302284PHASE3RECRUITINGA Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
NCT05340491PHASE3RECRUITINGChemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
NCT05342194PHASE3RECRUITINGToripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
NCT05980481PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
NCT06026878PHASE3RECRUITINGGNT Induction Treatment in Locally Advanced NPC
NCT06095583PHASE3RECRUITINGPhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06201065PHASE3RECRUITINGFOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
NCT06437977PHASE3RECRUITINGNeoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
NCT06441344PHASE3NOT_YET_RECRUITINGToripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell
NCT06592326PHASE3RECRUITING9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
NCT06647563PHASE3NOT_YET_RECRUITINGNeoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
NCT06984588PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT07111832PHASE3RECRUITINGA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
NCT07154069PHASE3RECRUITINGAdaptive Immunotherapy for Nasopharyngeal Carcinoma
NCT07177794PHASE3RECRUITINGConsolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
NCT07246330PHASE3NOT_YET_RECRUITINGStratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation–a Prospective, Randomized, Controlled Phase III Multicenter Study
NCT07332221PHASE3NOT_YET_RECRUITINGApplication of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial
NCT07340515PHASE3RECRUITINGProton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
NCT07371897PHASE3NOT_YET_RECRUITINGToripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial
NCT07445295PHASE3NOT_YET_RECRUITINGChiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT07540390PHASE3NOT_YET_RECRUITINGGAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
NCT07608224PHASE2/PHASE3NOT_YET_RECRUITINGHOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC
NCT03581786PHASE3COMPLETEDThe Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
NCT03829969PHASE3COMPLETEDToripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
NCT03859128PHASE2/PHASE3UNKNOWNToripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection
NCT03924050PHASE3UNKNOWNToripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
NCT03992911PHASE2/PHASE3UNKNOWNSafety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma
NCT04012606PHASE3COMPLETEDToripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer
NCT04085276PHASE3COMPLETEDToripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
NCT04568304PHASE3UNKNOWNA Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
NCT05056337PHASE3UNKNOWNToripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
NCT05669092PHASE3UNKNOWNA Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status
NCT05817201PHASE2/PHASE3UNKNOWNToripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
TMB HighLung Non-small Cell CarcinomaSensitivity/ResponseChemotherapy + ToripalimabCIViC BEID12798

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

4 molecules share ≥1 primary target. Top 4 by shared-target count:

MoleculeSourceStatusShared targets
PYRVINIUMChEMBLPhase 4 (approved)PDCD1
RIFABUTINChEMBLPhase 4 (approved)PDCD1
GefitinibPubChemApprovedPDCD1
PomalidomidePubChemApprovedPDCD1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot